Supercharged immunity solves ‘last-mile’ vaccine delivery challenge that could transform battles against cancer, pandemics, ...

The method triggers immune responses that inhibit melanoma, triple-negative breast cancer, lung carcinoma, and ovarian cancer ...

A study is seeking to contribute to cancer immunotherapy in the development of vaccines against deadly cancer types such as ...

EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach ...

RNA cancer vaccines are at the forefront of next-generation cancer immunotherapy, showcasing significant potential.

US FDA clears Everest Medicines’ IND application for tumour-associated antigen vaccine, EVM14: Shanghai, China Tuesday, March 25, 2025, 15:00 Hrs [IST] Everest Medicines, a biop ...

EVM14 received U.S. FDA clearance for its IND application, becoming Everest's first internally discovered program, and the first mRNA therapeutic cancer vaccine to be cleared for global clinical ...

The FDA cleared the investigational new drug (IND) application for EVM14. EVM14 is an off-the-shelf tumor-associated antigen ...

A team of researchers led by Dr. Kim V. Narry, director of the Center for RNA Research at the Institute for Basic Science ...

What’s Up With mRNA Research? A research nurse holds an injection of a BioNTech mRNA cancer immunotherapy for non-small cell ...

Immune response data from FLAMINGO-01 shows positive results in patients with HER2+ breast cancer, suggesting potential for ...

and the first mRNA therapeutic cancer vaccine to be cleared for global clinical development. Preclinical highlights： EVM14 induced a dose-dependent, antigen-specific immune response in mice and ...